Hypertension and nephrology

[Methods of using telemedicine devices (smartphones, tablets) during home blood pressure measurement]

KÉKES Ede

FEBRUARY 20, 2019

Hypertension and nephrology - 2019;23(01)

DOI: https://doi.org/10.33668/hn.23.005

[Despite the use of advanced antihypertensive drugs, patients with hypertension are still insufficient to reach the target blood pressure. In this area, home blood pressure measurement was a significant step forward, but it is not at all how the method of home blood pressure measurement is done, on the other hand, it needs to be much closer to the doctor-patient relationship. This is the goal of introducing telemedicine tools and methods into the every day clinical practice. Three methods are known: In the first one the user uses a special application on the smartphone and writes your data into the smartphone. Solution 2 is that data are automatically transferred from the measuring device into the smartphone in the third, the smartphone itself performs the measurement. Really, the first application can be disseminated with a broadly compatible doctor-patient collaboration strategy.]

COMMENTS

0 comments

Further articles in this publication

Hypertension and nephrology

[The importance of statin therapy in hypertension]

PARAGH György, PÁLL Dénes

[Hypertension and hypercholesterolaemia often co-occur and promote early cardiovascular disease. Previous studies have shown that antihypertensive treatment may be more effective if LDL cholesterol is also reduced. This may be due to the increased expression of angiotensin-1 receptor in hypercholesterolaemia, which increases peripheral vascular resistance through angiotensin-2, and adversely affects endothelial and smooth muscle cells. Other authors indicate that high cholesterol levels increase the production of angiotensin-2 through the activation of the chymase system. High cholesterol levels increase the amount of circulating oxidized LDL which binds to the transmembrane oxidized LDL receptor (LOX- 1) also activates the angiotensin-1 receptor. In addition, angiotensin-2 has an effect on intracellular cholesterol synthesis by enhancing the key enzyme of the synthesis of intracellular cholesterol, HMG-CoA reductase. The authors present the studies that support cholesterol lowering can contribute to lowering blood pressure and other major meta-analyses in which the beneficial effects of cholesterol lowering and lipid lowering on blood pressure reductions were not proven. In the background, it may well be that these studies are not designed to evaluate the effect of cholesterol-lowering drugs on hypertension in patients with hypercholesterolaemia, and non-statin-treated patients are not randomized.]

Hypertension and nephrology

[Carvedilol in chronic kidney disease]

CSIKY Botond

[Chronic kidney disease (CKD) is endemic affecting 850 million people worldwide. Adequate antihypertensive treatment slows the progression of the kidney disease and also decreases the mortality of this population. Because of the comorbidities and the high cardiovascular risk beta-blockers have to be administered frequently in these patients. Carvedilol is a 3rd generation non-selective beta-blocker with alpha- 1 receptor blocking and antioxidant properties. It is metabolically neutral, it does not increase the risk of new onset diabetes and it does not increase the patients’ body weight. In some animal models of CKD and in several human CKD studies carvedilol has shown to have nephroprotective properties and it also decreased the cardiovascular risk in combination therapies.]

Hypertension and nephrology

[Investigation of Diastolic Dysfunction and its Association with Complications in Hypertensive Patients ]

HATI Krisztina, POÓR Ferenc, VÁRALLYAY Zoltán

Hypertension and nephrology

[Obesity and Cardiovascular Risk. A Joint Action Program by ESH and EASO]

SIMONYI Gábor

Hypertension and nephrology

[The Szekszárd Hypertension Days]

BENCZÚR Béla

All articles in the issue

Related contents

Lege Artis Medicinae

[ANTIHYPERTENSIVE TREATMENT OF DIABETIC PATIENTS]

NAGY Viktor

[There are several evidence-based recommendations for the antihypertensive treatment of diabetic patients. The treatment should be chosen in such way that the target blood pressure (<130/80 Hgmm) is reached and the risk of target organ failure and cardiovascular mortality is minimized. Based on the studies, it seems that the angiotensin converting enzyme II receptor blockers and low-dose thiazide diuretics, along with their combinations can be recommended as first-line treatment in diabetes mellitus. Beta-receptor blockers and calciumchannel inhibitors are more effective than placebo and may be can be combined with angiotensin converting enzyme inhibitors, angiotensin converting enzyme II blockers and diuretics. This is important, because the effective antihypertensive treatment and the prevention of complications in diabetic patients can rarely be achieved with monotherapy only.]

Hypertension and nephrology

[Rilmenidin - a versatile combination partner in the treatment of high blood pressure]

KÉKES Ede

[The rilmenidin as an imidazoline agonist drug strongly decreases the central sympathetic activity, release of renine and the RAS activity. Because of these advantageous properties the peripheral vascular resistance falls and the blood pressure is decreased. Today it is excellent tool for combination therapy. Useful especially in stress induced hypertension. The antihypertensive effects of ACE inhibitors sor calcium antagonists are increased by rilmenidine. This drug decreases the insuline resistance, it has a positive effect on the carbohydrate and fat metabolism, because it is useful as a complementary therapy in metabolic syndrome and diabetes mellitus of type II. It is useful in stress induced hypertension, and in menopause as well.]

Hypertension and nephrology

[The importance of health-centered approach in the management of hypertensive patients]

VÁLYI Péter

[In the everyday clinical practice the main objectives are the accurate establishment of the diagnosis and evidence based treatment of diagnosed disease. Besides the accustomed, rigorously medical, simplifying aspect, the bio-psycho- social approach is gaining an increasing importance. The objective of the article is, taking modern definition of health into account, emphasizing the importance of a new approach in the complex management of patients, having primary hypertension, a disease, impairing not only target organs, as well as the whole person, seriously influencing the health status of the affected person. In the management of a hypertensive patient, besides decreasing blood pressure, preventing and treating target organ complications and coexisting diseases, we should assess the whole person impairment, the effects of environmental and personal factors, and their influence on activities of daily living and participation in the life of the society, consequently, the changes in health status. This complex approach permits alone the more complete restoration of health of an affected person.]

Lege Artis Medicinae

[Notes on the management of hypertension in chronic kidney disease ]

AMBRUS Csaba

[The prevalence of hypertension among pa­tients with chronic kidney disease is high, reaching more than 80%. Hypertension is both one of the main causes and also the most common consequence of chronic kidney disease. It is also a main factor responsible for the high cardiovascular morbidity and mortality in this patient population. Blood pressure control can improve patient outcomes, lower cardiovascular risk and slow down the progression of kidney dis­ease, irrespective of the underlying cause. The optimal therapy should therefore focus not only on blood pressure reduction but also on renoprotection. Basic understanding of the renal pathophysiology in hypertension and renal effects of various medications is of paramount importance. In this review, we summarized cornerstones of the antihypertensive therapy in patients with chronic kidney disease. The management of patients receiving kidney replacement therapies, such as hemodialysis, peritoneal dialysis or transplanta­tion requires special knowledge and expe­rience, therefore it is not discussed here. The aim of this review was to allow non-nephrologist physicians to take care of their kidney patients with more confidence and effectiveness.]

Lege Artis Medicinae

[CARDIOVASCULAR EFFECTS OF MENOPAUSAL HORMONE REPLACEMENT THERAPY]

PARAGH György, HARANGI Mariann

[The incidence of coronary heart disease in women rises sharply in the years following menopause. Hormone replacement therapy involves the administration of oestrogen, which provides postmenopausal symptom relief and reverses the changes in calcium and lipid metabolism. Moreover, oestrogen is also postulated to engage multiple mechanisms that defend against hypertension. Early observations suggested that postmenopausal women treated with hormone replacement therapy have significantly reduced cardiovascular risk. However, the results of primary and secondary prevention randomized clinical trials confirmed an increased cardiovascular risk rather than a beneficial effect of hormone replacement therapy in highrisk women. Controversy between results of observational and randomized clinical trials may partly be due to the unexplored genetic background. The authors summarize the effects of oestrogen on lipids, inflammation, haemostatic parameters, blood pressure and vascular wall. Genetic factors that modulate the effect of oestrogen as well as current recommendations on hormone replacement therapy after menopause in high risk women are also presented.]